Myriad Genetics | MYGN - Current Liabilities


Myriad Genetics reported $130.2M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agilent USD 2.23B 113M Dec/2025
Becton, Dickinson and Co. USD 8.51B 254M Mar/2026
Bio-Rad Laboratories USD 917M 400M Mar/2026
Bruker USD 1.36B 75.9M Mar/2026
Danaher USD 7.46B 653M Mar/2026
Illumina USD 1.57B 19M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Mettler Toledo International USD 1.11B 89.76M Mar/2026
Myriad Genetics USD 130.2M 3.6M Mar/2026
OraSure Technologies USD 44.08M 4.29M Mar/2026
Pacific Biosciences Of California USD 65.36M 7.48M Mar/2026
Quest Diagnostics USD 2.18B 101M Mar/2026
Quidel USD 962.4M 3.7M Mar/2026
Repligen USD 126.21M 9.62M Mar/2026
Revvity USD 1.24B 92.6M Mar/2026
Standard Biotools USD 42.2M 66.1M Mar/2026
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
Veracyte USD 56.11M 3.82M Mar/2026
Waters USD 1.24B 11.8M Dec/2025